Baxter International Inc.has announced that the FDA has approved Rixubis [Coagulation Factor IX (Recombinant)] for routine prophylactic treatment, control and...
Baxter International Inc. has announced that the company has submitted a marketing authorization application (MAA) to the European Medicines Agency...
On 23 October 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). RIXUBIS is indicated in patients of all age groups.
Baxalta, spun out of Baxter, launches on 1 July 2015 to develop and promote products in haematology, immunology and to...
Swedish Orphan Biovitrum AB and Biogen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP)...